Stephan Kudlacek

Stephan Kudlacek

Auto-generated profile, based on publicly available information

Stephan Kudlacek

Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Science Advances
Verified
Journal Article
Open access
SKStephan T. Kudlacek
Stephan T. Kudlacek
SMStefan Metz
Stefan Metz
DTDevina Thiono
Devina Thiono
APAlexander M. Payne
Alexander M. Payne
TPThanh T. N. Phan
Thanh T. N. Phan
BKBrian Kuhlman
Brian Kuhlman
A stabilized dimer of the surface protein from dengue virus has been engineered to elicit antibodies that neutralize the virus.

25 July 2023 in eLife
Verified
Journal Article
Open access
CLCan Liu
Can Liu
JZJiawei Zhou
Jiawei Zhou
SKStephan Kudlacek
Stephan Kudlacek
Timothy QiTimothy Qi
Timothy Qi
TDTyler Dunlap
Tyler Dunlap
YCyanguang cao
yanguang cao
Effector T cells need to form immunological synapses (IS) with recognized target cells to elicit cytolytic effects. Facilitating IS formation is the principal pharmacological action of most T cell-based cancer immunotherapies. However, the dynamics of IS formation at the cell population level, the primary driver of the pharmacodynamics of many cancer immunotherapies, remains poorly defined. Using classic immunotherapy CD3/CD19 bispecific T cell engager (BiTE) as our model system, we integrate experimental and theoretical approaches to investigate the population dynamics of IS formation and their relevance to clinical pharmacodynamics and treatment resistance. Our models produce experimentally consistent predictions when defining IS formation as a series of spatiotemporally coordinated events driven by molecular and cellular interactions. The models predict tumor-killing pharmacodynamics in patients and reveal trajectories of tumor evolution across anatomical sites under BiTE immunotherapy. Our models highlight the bone marrow as a potential sanctuary site permitting tumor evolution and antigen escape. The models also suggest that optimal dosing regimens are a function of tumor growth, CD19 expression, and patient T cell abundance, which confer adequate tumor control with reduced disease evolution. This work has implications for developing more effective T cell-based cancer immunotherapies.

18 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CLCan Liu
Can Liu
JZJiawei Zhou
Jiawei Zhou
SKStephan Kudlacek
Stephan Kudlacek
Timothy QiTimothy Qi
Timothy Qi
TDTyler Dunlap
Tyler Dunlap
YCyanguang cao
yanguang cao
Effector T cells form immunological synapses (IS) with recognized target cells to elicit cytolytic effects. Facilitating IS formation is the principal pharmacological action of most T cell-based cancer immunotherapies. However, the dynamics of IS formation at the cell population level, the primary driver of the pharmacodynamics of many cancer immunotherapies, remains poorly defined. With classic immunotherapy CD3/CD19 bispecific T cell engager (BiTE) as a model system, we integrate experimental and theoretical approaches to investigate the population dynamics of IS formation and their relevance to clinical pharmacodynamics and treatment resistance. Our models produce experimentally consistent predictions when defining IS formation as a series of spatiotemporally coordinated events driven by molecular and cellular interactions. The models predict tumor-killing pharmacodynamics in patients and reveal trajectories of tumor evolution across anatomical sites under BiTE immunotherapy. Our model highlight the bone marrow may serve as a sanctuary site permitting tumor evolution and antigen escape. The models also suggest the optimal dosing regimens as a function of tumor growth and patient T cell abundance that confer adequate tumor control with minimal disease evolution. This work has implications for developing more effective T cell-based cancer immunotherapies.